Table 2.
Participants’ demographic characteristics and PAP scores
| Total (N=347) | Japan (N=65) | Korea (N=54) | Nepal (N=49) | Iran (N=40) | Thailand (N=33) | India (N=19) | Others (N=87) | ||
|---|---|---|---|---|---|---|---|---|---|
| Age, years | 36.7±8.6 | 37.3±9.4 | 34.3±5.9 | 32.3±4.9 | 37.7±6.2 | 32.2±3.2 | 34.3±5 | 41.7±10.8 | |
| Male, N (%) | 212 (61) | 53 (82) | 44 (81) | 32 (65) | 12 (30) | 6 (18) | 14 (74) | 51 (59) | |
| Years of clinical experience | 8.5±7.8 | 8.8±8.9 | 6.5±5.7 | 4.9±4.0 | 8.0±6.0 | 5.8±2.7 | 7.3±4.3 | 12.7±9.8 | |
| PAP score (a total sum score after reverse scoring of *) | 12.6±3.0 | 11.7±2.7 | 15.3±2.1 | 11.3±2.9 | 13.4±2.6 | 12.5±2.6 | 10.6±2.7 | 12.4±3.0 | |
| Depending on the situation, it can be an important treatment option (not at all=1, extremely=5) | 3.5±1.2 | 3.2±1.1 | 4.4±0.6 | 2.9±1.1 | 3.6±1.0 | 3.5±1.1 | 3.1±1.4 | 3.6±1.1 | |
| Absolutely needs to be avoided (not at all=1, extremely=5)* | 2.5±1.2 | 2.6±1.1 | 1.7±0.7 | 3±1.2 | 2.1±1.1 | 2.8±1.0 | 2.9±1.4 | 2.7±1.3 | |
| Inevitable in severe cases (not at all=1, extremely=5) | 3.7±1.0 | 3.4±1.1 | 4.1±0.9 | 3.7±1.0 | 3.9±0.7 | 3.8±0.9 | 2.8±1.3 | 3.7±1.0 | |
| Are you careful to avoid polypharmacy in your usual clinical practice? (not at all=1, extremely=5)* | 4±1.0 | 4.3±0.7 | 3.2±0.9 | 4.2±1.0 | 4±0.9 | 4.1±0.8 | 4.5±1.0 | 4.2±1.0 | |
| Factors related to polypharmacy | |||||||||
| Policy factor | 2.9±2.1 | 4.8±1.0 | 2.4±1.9 | 1.9±1.8 | 1.4±1.3 | 4.5±1.6 | 2.2±2.1 | 2.6±2.0 | |
| Scientific factor | 4.1±1.9 | 3.4±2.0 | 3.1±1.8 | 5.1±1.3 | 2.5±2.1 | 4.3±1.5 | 5.3±1.2 | 4.9±1.4 | |
| Economic factor | 1.8±0.6 | 2.0±0.3 | 1.6±0.5 | 1.5±0.6 | 2.0±0.6 | 1.5±0.6 | 1.2±0.4 | 1.9±0.7 | |
| Clinical factor | 5.1±1.0 | 4.7±0.9 | 4.7±1.2 | 5.5±0.7 | 4.7±1.3 | 5.5±0.7 | 5.5±1.0 | 5.2±1.1 | |
PAP, Psychiatrists’ attitudes toward polypharmacy